Phoenix SENOLYTIX

Phoenix SENOLYTIX is a longevity-focused biotechnology company developing next-generation gene therapies designed to improve healthspan and extend lifespan. The company's core technology, ApoptiCIDe™, is a proprietary evolution of the clinically validated CaspaCIDe™ safety switch, enabling the purposeful elimination of specific cell populations in vivo. Phoenix's lead programs target senescent cells to combat aging-related decline and adipocytes to treat morbid obesity. As a subsidiary of GEROTHERAPEUTIX, the company leverages a hub-and-spoke model to advance its pipeline of controllable and regulated gene therapies. Phoenix maintains a strategic partnership with MD Anderson Cancer Center to expand the applications of its inducible switch technologies.